Acronym:
Pit
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Bowel and colon | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase I, Phase II | Tumour Stream | Colorectal |
| Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I, Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Colorectal |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
An open label phase I/II non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer.
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Royal Adelaide Hospital | Anne Milton | anne.milton@sa.gov.au | 08 7074 2342 | Nimit Singhal | Recruiting |
| The Queen Elizabeth Hospital | Sue Yeend | Sue.Yeend@sa.gov.au | 08 8222 6148 | Recruiting |